Isatuximab added to RVd boosts response in new myelomaDecember 13, 2021Multiple MyelomaHematologic Malignancies
Talk early to patients with high-risk AML about end-of-life decisionsDecember 12, 2021AMLHematologic Malignancies
Beta-thalassemia gene therapy achieves lasting transfusion independenceDecember 11, 2021Hematologic Malignancies
FDA approves time-saving combo for r/r multiple myelomaDecember 2, 2021Multiple MyelomaHematologic MalignanciesOncologyCancer
Decades spent searching for genes linked to rare blood cancerNovember 8, 2021Hematologic Malignancies
Evans’ Syndrome in Undiagnosed Small Lymphocytic Lymphoma: Case Report and Literature ReviewSeptember 10, 2021Hematologic Malignancies
Hemophagocytic Lymphohistiocytosis: Early Treatment Leading to an Excellent OutcomeSeptember 9, 2021Hematologic Malignancies
Targeted CLL treatments found effective in managing associated autoimmune cytopeniasJuly 15, 2021Hematologic Malignancies
Experimental antibody-drug conjugate shown active against r/r DLBCLJune 15, 2021Hematologic Malignancies
Choosing the right R-CHOP dosage for elderly patients with DLBCLJune 8, 2021OncologyHematologic MalignanciesGeriatrics
Patients with CLL have significantly reduced response to COVID-19 vaccine May 16, 2021COVID-19 UpdatesHematologic Malignancies
GENUINE improvements: Ublituximab plus ibrutinib for CLLApril 21, 2021OncologyHematologic Malignancies
CLL patients: Diagnostic difficulties, treatment confusion with COVID-19April 19, 2021COVID-19 UpdatesHematologic Malignancies
